Clinical trials: Myeloma, Plasma-Cell
Multiple Myeloma and Plasma Cell Neoplasm
Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00022607
- Testing
- bevacizumab, thalidomide
- Where
- 4 sites in United States
- Sponsor
- California Cancer Consortium
Chronic Myeloproliferative Disorders, Diamond-blackfan Anemia
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
RATIONALE: Giving chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's…
- Conditions
- Chronic Myeloproliferative Disorders, Diamond-blackfan Anemia, Fanconi Anemia, Graft Versus Host Disease
- Trial name
- NCT00290628
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Asymptomatic Myeloma
Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma
The purpose of this pilot study is to gain initial insights into the biologic and clinical effects of Atezolizumab in patients with Asymptomatic Multiple Myeloma (AMM).
- Trial name
- NCT02784483
- Testing
- Atezolizumab (1200mg via IV infusion)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Yale University
Multiple Myeloma and Plasma Cell Neoplasm
Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Oblimersen may increase the effectiveness of dexamethasone by making cancer cells more sensitive to the…
- Trial name
- NCT00017602
- Testing
- oblimersen sodium, dexamethasone
- Where
- United States
- Sponsor
- Genta Incorporated
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide
This randomized phase II trial studies how well pomalidomide and dexamethasone work compared to lenalidomide and dexamethasone in treating patients with multiple myeloma that has returned after a period of improvement (relapsed)…
- Trial name
- NCT01794039
- Testing
- Dexamethasone, Lenalidomide, Pomalidomide
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Mayo Clinic
Myeloma
Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple Myeloma
An Open-Label Study of the Efficacy and Safety of Oral CEP-701 for the Treatment of Patients with Advanced Multiple Myeloma.
- Trial name
- NCT00242827
- Testing
- Oral CEP-701
- Where
- 5 sites in United States
- Sponsor
- Cephalon
Multiple Myeloma
S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
RATIONALE: Thalidomide may stop the growth of cancer cells by stopping blood flow to the cancer. Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00040937
- Testing
- filgrastim, sargramostim, cyclophosphamide
- Where
- 141 sites in United States
- Volunteers
- 147 people
- Sponsor
- SWOG Cancer Research Network
Chronic Lymphocytic Leukemia, Graft vs Host Disease
The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers
Cancers of the blood, sometimes referred to as hematologic malignancies, are disorders of bone marrow cells that lead to the failure of the normal function of bone marrow and the uncontrolled growth of cancerous cells in the bone…
- Conditions
- Chronic Lymphocytic Leukemia, Graft vs Host Disease, Hematologic Neoplasm, Multiple Myeloma
- Trial name
- NCT00001873
- Testing
- Isolex 300i plus MoAbs
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Myeloma
Long-Term Follow Up Study for AMD3100 Patients
Objectives: The objective of this long-term observational study is to assess progression-free survival and overall survival for a period of five years following the first dose of study treatment (placebo or plerixafor [AMD3100])…
- Trial name
- NCT00476294
- Testing
- Telephone Questionnaire
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma, Non-Hodgkin Lymphoma
PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients
This is a phase II study to evaluate the efficacy and safety of TG-0054 combined with G-CSF in mobilizing hematopoietic stem cells in patients with multiple myeloma, non-Hodgkin lymphoma or Hodgkin disease.
- Conditions
- Multiple Myeloma, Non-Hodgkin Lymphoma, Hodgkin Disease
- Trial name
- NCT02104427
- Testing
- TG-0054 combined with G-CSF
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- GPCR Therapeutics, Inc.
Multiple Myeloma
Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
The purpose of the study is to determine whether the combination of LDE225 (sonidegib) plus bortezomib is safe and effective in the treatment of relapsed or relapsed/refractory multiple myeloma.
- Trial name
- NCT02254551
- Testing
- LDE225, Bortezomib
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- SCRI Development Innovations, LLC
Multiple Myeloma
IFM 99-02 Thalidomide in Myeloma
Principal objective is to evaluate the impact of Thalidomide to prolong the duration of response after autologous transplantation for myeloma
- Trial name
- NCT00222053
- Testing
- Thalidomide, Biphosphonates
- Where
- 5 sites in France
- Volunteers
- 800 people
- Sponsor
- University Hospital, Toulouse
Multiple Myeloma
Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro
The purpose of this study is to better understand what effects Bortezomib, a drug used for multiple myeloma therapy, has on the immune system.
- Trial name
- NCT01472627
- Testing
- Blood draws
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Dana-Farber Cancer Institute
B-cell Non Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia
Treatment of Hematological Malignancy With Novel CAR-T Cells.
This is a single arm, open-label, early phase I study, to determine the safety and efficacy of Novel CAR-T cell therapy in Hematological Malignancy treatment.
- Conditions
- B-cell Non Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia, Multiple Myeloma
- Trial name
- NCT04191941
- Testing
- Novel CAR-T
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Timmune Biotech Inc.
Multiple Myeloma, Cutaneous Lymphoma
ATRA Plus G-CSF for Mobilization of Hematopoietic Stem and Progenitor Cells
Hematopoietic stem and progenitor cells (HSPC) are used for transplantation in patients undergoing high dose therapy for the treatment of a range of cancers.
- Trial name
- NCT00400556
- Testing
- ATRA plus G-CSF (filgrastim, NEUPOGEN (R)) combination
- Where
- Australia
- Volunteers
- 6 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Cancer, Adult Solid Tumor
Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors
Many patients are treated for advanced cancer without knowledge of underlying molecular features that might indicate FDA approved therapies or potential eligibility for biomarker-selected clinical trials.
- Conditions
- Cancer, Adult Solid Tumor, Lymphoma, Multiple Myeloma
- Trial name
- NCT03061305
- Where
- 40 sites in United States
- Volunteers
- 58,213 people
- Sponsor
- Strata Oncology
Autologous Hematopoietic Stem Cell Transplant
Muscle Stimulation for Physical Function During Stem Cell Transplant
Some blood, bone marrow, and lymphatic (hematologic) cancers such as Hodgkin/Non-Hodgkin lymphomas, chronic lymphocytic leukemia, and multiple myeloma, are over-represented in Veterans due to exposures including Agent Orange and…
- Trial name
- NCT04364256
- Testing
- RS-4i Plus Sequential Stimulator (RS Medical, Vancouver, WA)
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- VA Office of Research and Development
Cancer, Myeloma
Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
OBJECTIVES Primary: To evaluate the bone anabolic effect of bortezomib in patients with smoldering myeloma. Secondary: To evaluate the effect of bortezomib on the natural history of smoldering myeloma.
- Conditions
- Cancer, Myeloma, Multiple Myeloma
- Trial name
- NCT00983346
- Testing
- Bortezomib
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Utah
Plasma Cell Myeloma
Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission
This study will test whether stopping maintenance therapy in people with multiple myeloma in MRD-negative remission has the same effect on disease control as continuing this therapy.
- Trial name
- NCT04221178
- Testing
- Cessation of continuous matinenace therapy
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Vertebral Fracture, Multiple Myeloma
Examination of Vertebroplasty in Addition to Regular Treatment of Patients With Multiple Myeloma.
Patients with newly diagnosed or known multiple myeloma with newly diagnosed vertebral lesion(s) will be invited to participate in a cross-sectoral randomized controlled trial.
- Trial name
- NCT04533217
- Testing
- Vertebroplasty
- Where
- Denmark
- Volunteers
- 90 people
- Sponsor
- Spine Centre of Southern Denmark
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.